AbbVie Inc. buy Piper Jaffray Companies
Start price
17.12.24
/
50%
€167.22
Target price
17.12.25
€209.70
Performance (%)
17.76%
Price
12.12.25
€190.40
This prediction will end soon
Summary
This prediction is currently active. The BUY prediction by Piper_Jaffray_Compan currently has a performance of 17.76%. Dividends of €6.51 are taken into consideration when calculating the performance. This prediction currently runs until 17.12.25. The prediction end date can be changed by Piper_Jaffray_Compan at any time. Piper_Jaffray_Compan has 50% into this predictionAbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| AbbVie Inc. | -1.957% | -1.957% |
| iShares Core DAX® | 0.734% | -0.964% |
| iShares Nasdaq 100 | -2.686% | -2.409% |
| iShares Nikkei 225® | -2.261% | -4.038% |
| iShares S&P 500 | -1.346% | -1.510% |
Comments by Piper_Jaffray_Compan for this prediction
In the thread AbbVie Inc. diskutieren
AbbVie Inc. (NYSE: ABBV) had its "overweight" rating re-affirmed by analysts at Piper Sandler Companies. They now have a $220.00 price target on the stock.
Ratings data for ABBV provided by MarketBeat